BioXcel Therapeutics receives Nasdaq delisting notice; intends to appeal

BioXcel Therapeutics, Inc.

Received Nasdaq delisting notice on March 20, 2025 for failing to meet $35M minimum MVLS requirement.
Company was granted 180-day period through March 19, 2025 to regain compliance but remained non-compliant.
Intends to timely request a hearing before Nasdaq Hearings Panel to appeal the staff's determination.
Appeal will stay delisting action pending outcome; common stock remains listed on Nasdaq in interim.
No assurance that Company will ultimately regain compliance and remain listed on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.